Skip to main content
Premium Trial:

Request an Annual Quote

Whatman Gets New Finance Chief and COO; MDS Pharma Hires Strategy VP; Devgen Appoints Chairman; and Others

NEW YORK (GenomeWeb News) — Belgian biomarker company Pronota has appointed John Berriman chairman. Berriman was chairman of Algeta and is a director at MicroMet, Ablynx, and Oxxon Therapeutics.
He had been a director at Abingworth Management, worked at Celltech Group and Celltech Therapeutics, and founded Celltech Biologics. Berriman also was a director and co-founder at Solexa, chairman of Chroma Therapeutics, and was a director at Epigenomics, Alnylam, and XCounter AB.

Whatman has tapped Chris Rickard to replace Phil Greenhalgh as finance director. Rickard comes to Whatman from VT Group, where he was finance director.
The company also said that Ian Bonnar will leave his post as chief operating officer. He will be replaced by Manfred Baumann.

The America Statistical Association has named as a fellow Russell Wolfinger, SAS Institute’s director of scientific discovery and genomics.
ASA fellows are recognized for contributions to and leadership in statistical science.
Wolfinger will be honored at a ceremony on July 31 at the ASA Joint Statistical Meeting in Salt Lake City.

MDS Pharma Services has appointed Todd Johnson to be senior vice president of strategy and corporate development.
Johnson previously was a strategic consultant for pharmaceutical and biotechnology companies at McKinsey & Company. He also was CEO of Tangerine Technologies and was a cancer researcher at Harvard’s Dana-Farber Cancer Institute, the University of Pennsylvania, and at the National Institutes of Health

Belgian company Devgen has appointed Pol Bamelis to be chairman of the board.
Bamelis has been chairman of the Agfa group and a director at Bayer and the University of Leuven.

Jing Zhang has been awarded the 2007 Alzheimer’s Award by the Journal of Alzheimer’s Disease. The journal gave Zhang the award for the paper “Detection of Biomarkers with a Multiplex Quantitative Proteomic Platform in Cerebrospinal Fluid of Patients with Neurodegenerative Disorders,” which resulted from a study Zhang led that included a number of other researchers.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.